Triumph Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.6K Hold
200
– – ﹤0.01% 1214
2026
Q2
$7.82K Buy
+200
New +$6.17K ﹤0.01% 1221
2026
Q1
– Sell
-200
Closed -$8.57K – 1884
2025
Q4
$8.57K Buy
+200
New +$7.54K ﹤0.01% 1127

Other funds holding RIGL

Triumph Capital Management's RIGL Position: Q3 2026 in Review

Triumph Capital Management held its Rigel Pharmaceuticals (RIGL) position steady in Q3 2026 at 200 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Triumph Capital Management first reported a position in RIGL in Q4 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

  • Triumph Capital Management held 200 shares of Rigel Pharmaceuticals worth $9.6K as of Q3 2026.
  • Triumph Capital Management left its Rigel Pharmaceuticals share count unchanged in Q3 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1214 holding.
  • Triumph Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.